Darzalex
E49853
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Darzalex canonical | 3 |
| Darzalex Faspro | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T391439 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Darzalex Context triple: [Johnson & Johnson, notableProduct, Darzalex]
-
A.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Darzalex Target entity description: Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
A.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
Tysabri
Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Plegridy
Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
anticancer drug
ⓘ
immunotherapy ⓘ monoclonal antibody drug ⓘ pharmaceutical drug ⓘ |
| affectsLaboratoryTest | indirect antiglobulin test ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| canInterfereWith | blood compatibility testing ⓘ |
| commonAdverseEffect |
fatigue
ⓘ
infusion-related reactions ⓘ nausea ⓘ neutropenia ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| contraindication | severe hypersensitivity to daratumumab ⓘ |
| developedBy | Genmab ⓘ |
| firstApprovedForIndication | treatment of patients with multiple myeloma who have received at least three prior lines of therapy ⓘ |
| hasActiveIngredient | daratumumab ⓘ |
| hasATCCode | L01XC24 ⓘ |
| hasBlackBoxWarning | infusion-related reactions ⓘ |
| hasDosageForm |
concentrate for solution for infusion
ⓘ
solution for subcutaneous injection ⓘ |
| hasDrugClass |
CD38-directed monoclonal antibody
ⓘ
monoclonal antibody ⓘ |
| hasInternationalNonproprietaryName | daratumumab ⓘ |
| hasMechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
ⓘ
induces apoptosis of CD38-expressing cells ⓘ induces complement-dependent cytotoxicity ⓘ modulates immune microenvironment ⓘ |
| hasRouteOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| indicatedFor |
multiple myeloma
ⓘ
newly diagnosed multiple myeloma ⓘ refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| marketedBy |
Janssen Biotech
ⓘ
Janssen-Cilag ⓘ
linked to:
Janssen Pharmaceuticals
|
| requiresPremedication |
antihistamines
ⓘ
antipyretics ⓘ corticosteroids ⓘ |
| targets | CD38 ⓘ |
| usedInCombinationWith |
bortezomib
ⓘ
dexamethasone ⓘ lenalidomide ⓘ melphalan ⓘ pomalidomide ⓘ prednisone ⓘ thalidomide ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Darzalex Description of subject: Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.